Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS)

Italian MS Register, Damiano Paolicelli, Giuseppe Lucisano, Alessia Manni, Carlo Avolio, Simona Bonavita, Vincenzo Brescia Morra, Marco Capobianco, Eleonora Cocco, Antonella Conte, Giovanna De Luca, Francesca De Robertis, Claudio Gasperini, Maurizia Gatto, Paola Gazzola, Giacomo Lus, Antonio Iaffaldano, Pietro Iaffaldano, Davide Maimone, Giulia MallucciGiorgia T Maniscalco, Girolama A Marfia, Francesco Patti, Ilaria Pesci, Carlo Pozzilli, Marco Rovaris, Giuseppe Salemi, Marco Salvetti, Daniele Spitaleri, Rocco Totaro, Mauro Zaffaroni, Giancarlo Comi, Maria Pia Amato, Maria Trojano

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: The increase in disease-modifying drugs (DMDs) allows individualization of treatment in relapsing multiple sclerosis (RMS); however, the long-term impact of different treatment sequences is not well established. This is particularly relevant for MS patients who may need to postpone more aggressive DMD strategies.OBJECTIVE: To evaluate different therapeutic strategies and their long-term outcomes, measured as relapses and confirmed disability progression (CDP), in MS 'real-world' settings.METHODS: Multicentre, observational, retrospectively acquired cohort study evaluating the long-term impact of different treatment strategies on disability outcomes in patients with RMS in the Italian MS Register.RESULTS: We evaluated 1152 RMS-naïve patients after propensity-score adjustment. Patients included were receiving: interferon beta-1a (IFN-β1a) 44 µg switching to fingolimod (FTY; IFN-switchers; n = 97); FTY only (FTY-stayers; n = 157); IFN-β1a only (IFN-stayers; n = 849). CDP and relapses did not differ between FTY-stayers and IFN-switchers [HR (95% CI) 0.99 (0.48-2.04), p = 0.98 and 0.81 (0.42-1.58), p = 0.55, respectively]. However, IFN-stayers showed increased risk of relapses compared with FTY-stayers [HR (95% CI) 1.46 (1.00-2.12), p = 0.05].CONCLUSION: The ideal treatment option for MS is becoming increasingly complex, with the need to balance benefit and risks. Our results suggest that starting with FTY affects the long-term disease outcome similarly to escalating from IFN-β1a to FTY.
Original languageEnglish
JournalJournal of Neurology
DOIs
Publication statusPublished - Sep 18 2019

Fingerprint Dive into the research topics of 'Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS)'. Together they form a unique fingerprint.

Cite this